Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Up 243.1% in January

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the recipient of a large growth in short interest in January. As of January 31st, there was short interest totalling 1,536,000 shares, a growth of 243.1% from the January 15th total of 447,700 shares. Based on an average trading volume of 2,008,300 shares, the short-interest ratio is currently 0.8 days.

Bayer Aktiengesellschaft Stock Up 0.9 %

Shares of BAYRY traded up $0.05 during mid-day trading on Thursday, reaching $5.52. The company’s stock had a trading volume of 648,213 shares, compared to its average volume of 1,011,742. The company has a market cap of $21.69 billion, a price-to-earnings ratio of -21.23 and a beta of 1.04. The company has a quick ratio of 0.81, a current ratio of 1.32 and a debt-to-equity ratio of 1.19. Bayer Aktiengesellschaft has a 1 year low of $4.79 and a 1 year high of $8.58. The business has a fifty day moving average of $5.24 and a 200 day moving average of $6.43.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.10). Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.90%. The business had revenue of $10.96 billion during the quarter. As a group, analysts forecast that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.